Recently Updated Protein-based XBB COVID Vaccine Sparks Neutralizing Responses Against Emerging Subvariants – Shiv Telegram Media

Novavax’s Protein-Based COVID Vaccine Shows Promising Results Against Emerging Subvariants

Novavax, Inc. has recently announced that its protein-based XBB COVID vaccine candidate has demonstrated promising results in generating neutralizing antibody responses against emerging subvariants, including EG.5.1 and XBB.1.16.6. These subvariants are responsible for the majority of current COVID cases in both the United States and the European Union.

Previous studies have also shown that Novavax’s COVID vaccine candidate triggers immune responses against other variants, such as XBB.1.5, XBB.1.16, and XBB.2.3. These findings indicate a broad response that could potentially be effective against future variants.

If regulatory bodies grant approval, Novavax’s protein-based COVID vaccine would emerge as the only non-mRNA vaccine option available in key markets for the upcoming fall season.

Novavax has been actively collaborating with global regulatory bodies to expedite the availability of its protein-based vaccine by fall.

Despite not yet securing approval or licensing from the U.S. Food and Drug Administration (FDA), the Novavax COVID-19 Vaccine, Adjuvanted has received emergency use authorization for individuals aged 12 and above to prevent COVID-19.

Furthermore, the vaccine has also been authorized for providing a booster dose at least six months after completing the primary vaccination for individuals aged 18 and above, who have previously received an authorized or approved COVID-19 vaccine.

Novavax advises against administering the vaccine to individuals with a history of severe allergic reactions to any component of the vaccine.

Adverse reactions associated with the vaccine, such as injection site pain, fatigue, muscle pain, headache, fever, and hypersensitivity reactions, have been reported.

Novavax recommends closely monitoring recipients for immediate adverse reactions and ensuring the availability of appropriate medical treatment in case of an acute allergic response.

There is evidence suggesting an increased risk of myocarditis and pericarditis following the administration of the Novavax COVID-19 Vaccine, Adjuvanted. To address these concerns, the Centers for Disease Control and Prevention (CDC) has provided considerations related to these conditions after vaccination.

Novavax also advises that fainting may occur after receiving the vaccine, and precautionary measures should be in place to prevent any potential injuries.

Individuals with compromised immune systems may have a reduced immune response to the vaccine.

It is important to note that the Novavax COVID-19 Vaccine, Adjuvanted may not provide full protection for all recipients.

Adverse events, vaccine administration errors, cases of myocarditis and pericarditis, Multisystem Inflammatory Syndrome cases, as well as instances of COVID-19 resulting in hospitalization or death, should be reported to the Vaccine Adverse Event Reporting System (VAERS).

Novavax is actively working towards developing an updated COVID vaccine for the fall vaccination season in 2023.

However, Novavax cautions that there are inherent risks and uncertainties that could impact the scope, timing, and outcome of regulatory filings and actions concerning their vaccine candidates.